Application and Enlightenment of WHO Drug Pricing Method in Medical Insurance Pricing of Proprietary Chinese Medicine in China
- VernacularTitle:WHO药品定价方法在我国中成药医保定价中的应用与启示
- Author:
Yijiu YANG
1
;
Bin LIU
;
Haili ZHANG
;
Ning LIANG
;
Tian SONG
;
Wenjie CAO
;
Huizhen LI
;
Xingyu ZONG
;
Weili WANG
;
Dingyi WANG
;
Ziteng HU
;
Yanping WANG
;
Sheng HAN
;
Nannan SHI
Author Information
1. 中国中医科学院中医临床基础医学研究所 北京 100700
- Keywords:
World Health Organization;
pricing of traditional Chinese medicine;
value-based pricing;
review
- From:
Chinese Health Economics
2023;42(12):53-56
- CountryChina
- Language:Chinese
-
Abstract:
WHO Guideline on Country Pharmaceutical Pricing Policies,published in 2020,outlines 10 commonly used pricing methods internationally.However,due to the unique composition of costs for traditional Chinese medicine(TCM),directly applying pricing methods designed for chemical and biological drugs may lead to discrepancies.Currently,in China,drug pricing primarily in-volves internal reference pricing,tender negotiation pricing,promoting the use of quality-assured generic and biosimilar drugs,and centralized procurement.It systematically analyzes various pricing methods and identifies their applicability and underlying reasons concerning the pricing of TCMwithin the medical insurance system.The method of value-based pricing and increasing price transparency has advantages for the pricing regulation of traditional Chinese medicine under medical insurance.
